NovaBridge Biosciences Conference Call Summary Company Overview - **Company Name**: NovaBridge Biosciences (formerly I-Mab) - **Industry**: Biotechnology - **Focus**: Transitioned from an asset-based biotech company to a platform company aimed at bringing Chinese innovations to global markets [2][3] Key Points Business Transformation and Strategy - **Name Change**: The company rebranded from I-Mab to NovaBridge to reflect its new strategy [2] - **Strategic Pivot**: Shifted focus to leverage the Chinese biotech ecosystem for global innovation, recognizing the increase in in-licensing deals from 10% to 40% over three years [3] - **Competitive Advantage**: NovaBridge combines strong access to the Chinese biotech ecosystem with established operations in the U.S., differentiating it from many competitors [5][6] Givastomig Development - **Clinical Data**: Givastomig shows promising results in combination with Nivolumab and chemotherapy for gastroesophageal adenocarcinoma, with a progression-free survival (PFS) of approximately 17 months, significantly better than existing treatments [11][15] - **Efficacy Consistency**: The data shows consistent objective response rates of 70%-80% across various patient subgroups [15][16] - **Comparison with Competitors**: Givastomig's PFS is superior to other treatments like CheckMate 649 (7.7 months) and SPOTLIGHT (10.5 months) [15][16] - **Safety Profile**: The treatment has a manageable toxicity profile, with gastritis being the only notable side effect [11][19] Future Development Plans - **Clinical Trials**: Plans to conduct randomized trials to validate the efficacy of Givastomig, addressing concerns about single-arm study limitations [15][30] - **Patient Stratification**: Future studies will focus on patients with claudin 18.2 expression levels of 1% or greater, ensuring a representative patient population [26][29] VIS-101 Update - **Clinical Data**: VIS-101 demonstrated favorable safety and efficacy, with two-thirds of patients remaining treatment-free for four months and half for six months, outperforming Vabysmo [42][43] - **Mechanism of Action**: The molecule targets VEGF-A and Ang2, showing a twofold improvement in VEGF-A and a 17-fold improvement in Angiopoietin-2 binding affinity compared to competitors [50][51] IPO Plans - **Hong Kong IPO**: The company is adjusting its IPO plans due to regulatory requirements, aiming for a valuation that reflects its pipeline's inherent value before proceeding [60] Market Competition - **Competitive Landscape**: The gastric cancer treatment market is becoming increasingly competitive, with multiple companies developing similar therapies. NovaBridge aims to position Givastomig as a best-in-class option [30][34] Additional Insights - **Regulatory Engagement**: Positive interactions with the FDA regarding Givastomig's development strategy indicate strong regulatory support [34] - **Future Innovations**: The company is exploring novel bispecific and tri-specific agents to enhance its therapeutic offerings [38] Conclusion NovaBridge Biosciences is strategically positioned to leverage its unique access to the Chinese biotech ecosystem while developing promising therapies like Givastomig and VIS-101. The company is focused on rigorous clinical validation and regulatory engagement to ensure successful market entry and competitive positioning in the biotechnology landscape.

NovaBridge Biosciences Update Summary Company Overview - **Company**: NovaBridge Biosciences (NasdaqGM:IMAB) - **Focus**: Global biotech platform with a hub-and-spoke business model, primarily in ophthalmology and oncology sectors - **Lead Assets**: - **VIS-101**: A molecule targeting VEGF-A and ANG-2, designed for retinal vascular diseases - **Givastomig**: A bispecific antibody for gastric cancer, targeting Claudin 18.2 and 4-1BB - **Financial Position**: As of the last SEC filing, the company has $228 million in cash, providing operational runway through 2028 [5][6] Industry Context - **Market Need**: Over 57 million people globally are affected by retinal vascular diseases, including wet AMD, diabetic macular edema, and retinal vein occlusion, indicating a significant unmet need for effective therapies [16][17] - **Competitive Landscape**: Current treatments like Lucentis and Eylea have shorter treatment intervals, while VIS-101 aims for longer intervals (Q8 to Q24 weeks) [18][19] Clinical Development - **VIS-101 Phase IIa Trial**: - **Design**: Multicenter, open-label, randomized study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with neovascular AMD [25][26] - **Patient Population**: 38 patients randomized in a 2-to-1 ratio to receive either 6 mg or 3 mg of VIS-101 [26] - **Results**: - Rapid and robust BCVA gain observed, with approximately 70% of treatment-naive patients being treatment-free at 4 months and about 40% at 6 months [31][32] - Central subfield thickness (CST) decreased by over 100 microns after the first injection [31] - Safety profile: Well-tolerated with no dose-limiting toxicities reported [34] Key Findings - **Durability**: VIS-101 demonstrated a potential best-in-class durability with treatment-free intervals extending up to 24 weeks [40] - **Comparison with Competitors**: VIS-101 shows double the anti-VEGF inhibition and 17 times the anti-ANG-2 inhibition compared to faricimab [35] - **Management Team**: Led by experienced professionals, including Dr. Emmett Cunningham, who has a strong background in ophthalmology and drug development [11][12] Future Plans - **Next Steps**: - Initiation of Phase IIb study in China in the second half of 2026 - Global Phase III program expected to begin in 2027 [40][41] - **Partnership Strategy**: Open to discussions for partnerships but currently does not require one for global development [70] Additional Insights - **Clinical Trial Design**: The trial's retreatment criteria were designed to prioritize patient safety, requiring either a decrease in vision or an increase in anatomical parameters for retreatment [53] - **Regulatory Considerations**: Future trials will likely focus on treatment-naive patients, as regulatory agencies prefer this population for clearer efficacy assessments [79] This summary encapsulates the key points from the NovaBridge Biosciences update, highlighting the company's strategic focus, clinical advancements, and future directions in the biotech landscape.

Core Insights - Tianjing Biopharma has signed a collaboration agreement with Zhijiang Laboratory Technology Holdings to develop next-generation long-acting innovative biologics, including growth hormones, aimed at providing more convenient treatment options for patients [1][5]. Company Overview: Tianjing Biopharma - Tianjing Biopharma focuses on innovative therapies for autoimmune diseases, tumor immunology, and metabolic diseases, with a differentiated dual-tier innovative drug pipeline [6]. - The first tier includes three products (Fizetuzumab, Eitan Growth Hormone α, and Idaglutide α) that have entered the product listing acceptance stage, while four additional innovative products are in the registration clinical stage or about to start Phase III clinical trials [6]. - The second tier consists of First-in-Class innovative drug projects based on the AntibodyPLUS platform, which are about to enter Phase I clinical trials or initiate clinical applications [6][7]. - The company is accelerating the internationalization of its innovative drug pipeline and integrating R&D, production, and product listing processes in China through collaborations with partners like Jichuan Pharmaceutical, Shiyao Group, and Sanofi [7]. Company Overview: Zhijiang Laboratory Technology Holdings - Zhijiang Laboratory Technology Holdings was established on September 27, 2020, to accelerate the application of technological achievements in the field of intelligent computing and to serve the development of the digital economy and emerging industries [8]. - The company has a registered capital of 100 million yuan and is located in the Future Technology City AI Town in Yuhang District, Hangzhou [8]. - Zhijiang Holdings is dedicated to providing high-quality full-chain services for the transformation and industrialization of technological achievements, including basic services like policy promotion and project due diligence, as well as value-added services such as concept verification and financing [8]. Collaboration Insights - The collaboration will leverage Zhijiang Laboratory's AI-driven research discovery platform, BioDeepDiscovery (BDD), while Tianjing Biopharma will contribute its extensive R&D experience, biological data, and preclinical research capabilities [2][6]. - The partnership aims to combine the strengths of both companies to accelerate drug development processes, particularly in exploring long-acting innovative biologics across multiple therapeutic areas [2][6].

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has established strategic partnerships with major players in the industry to enhance its research and development efforts [1] Price Target Analysis - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past month, indicating a more cautious short-term outlook from analysts [2][5] - Despite the recent decrease, the price target has remained stable over the past year, suggesting a consistent long-term view of the company's potential [2] Comparative Analysis with IMab - IMab has been upgraded to a Zacks Rank 2 (Buy), with a new price target of $8 set by analyst Kumaraguru Raja, reflecting increased optimism about its earnings potential [3][5] - The contrasting outlooks for NovaBridge and IMab highlight varied analyst sentiments based on recent developments in the biotech sector [4][5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in clinical trials and strategic partnerships enhancing its capabilities [1] - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past year, indicating a decline in analyst optimism [2][5] - Recent changes in the price target may be influenced by clinical trial developments, strategic partnerships, or broader market conditions affecting the biotech sector [3] Company Overview - NovaBridge is developing promising immuno-oncology agents such as givastomig, uliledlimab, and ragistomig, which are at various clinical trial stages [1] - The company has established strategic partnerships with major players like Ferring International Center SA, Bristol Myers Squibb, ABL Bio, Inc., and TJ Bio [1] Market Comparison - In contrast to NovaBridge, IMab has been upgraded to a Zacks Rank 2 (Buy), with a price target of $8, indicating increased optimism regarding its earnings potential [4] - The differing analyst views on NovaBridge and IMab highlight the varying expectations within the biotech sector [5]

Core Viewpoint - NovaBridge Biosciences, formerly known as I-Mab, has undergone a corporate name change and will begin trading under the new ticker symbol "NBP" on Nasdaq starting October 30, 2025, as part of its strategic transformation into a global biotechnology platform company focused on innovative medicines [1][2][3] Corporate Transformation - The new corporate brand and website signify a strategic shift towards becoming a global biotechnology platform committed to accelerating access to innovative medicines for patients worldwide [2] - The name change was overwhelmingly approved by shareholders and the Board of Directors during an Extraordinary General Meeting held on October 24, 2025 [1] Business Strategy - The company plans to pursue a dual listing on both Nasdaq and the Hong Kong Stock Exchange (HKEX) to broaden its investor base and enhance trading liquidity [6][7] - NovaBridge has adopted a "hub-and-spoke" business model, creating specialized subsidiary companies to maintain operational focus and agility [9] Pipeline and Product Development - The core asset, givastomig, is a potential best-in-class Claudin 18.2-directed therapy for gastric cancers, currently advancing towards a global randomized Phase 2 study with first patient enrollment expected in Q1 2026 [8][12] - VIS-101, acquired by the newly formed subsidiary Visara, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development and anticipated to be Phase 3-ready in 2026 [11][16] Leadership and Expertise - The company is led by experienced professionals, including Dr. Emmett T. Cunningham, Jr., who has extensive expertise in infectious and inflammatory eye disease [11][12] - NovaBridge aims to leverage deep local insights and global capabilities to develop promising drug candidates across various therapeutic categories [8][13]

Core Insights - I-Mab announced updated data from the Phase 1 study of givastomig, a bispecific antibody targeting CLDN18.2 and 4-1BB, showing an 18% objective response rate (ORR) in heavily pre-treated gastroesophageal carcinoma patients [1][2][7] Study Data Summary - The Phase 1 study involved 45 patients with a median of 3 prior therapies, demonstrating an ORR of 18% with responses across a dose range from 5 mg/kg Q2W to 18 mg/kg Q3W [2][7][13] - No differences in efficacy were observed across varying levels of CLDN18.2 expression, with a disease control rate (DCR) of 49% [7][13] - The median progression-free survival (mPFS) was 2.96 months and median overall survival (mOS) was 7.49 months [13] Safety Profile - Givastomig was well tolerated, with no dose-limiting toxicities reported, and common treatment-related adverse events (TRAEs) included anemia (27%), white blood cell count decrease (22%), and nausea (20%) [10][13] Future Plans - I-Mab plans to report topline results from the Phase 1b dose expansion study and initiate a global randomized Phase 2 study in Q1 2026 [2][7] - The upcoming presentation at the Triple Meeting on October 23, 2025, will provide further insights into the safety and efficacy of givastomig [4][5] Market Potential - The treatment strategy for givastomig is anchored in the first-line gastric cancer market, which is estimated to be a $2 billion potential market [7]

Group 1 - Recent years have seen a trend of Chinese concept stocks returning to Hong Kong for listing, with companies like Hesai Technology, Tianjing Biotechnology, WeRide, and Pony.ai announcing their plans or progress for Hong Kong listings [1][2] - Pony.ai plans to issue up to 102.1 million shares and has a current market value exceeding $7 billion, while Tianjing Biotechnology aims for a dual listing in Hong Kong to enhance collaboration with global innovators and diversify its investor base [1][2] - WeRide has received approval from the China Securities Regulatory Commission for its Hong Kong listing, intending to issue up to 102.4 million shares, and is noted for holding autonomous driving licenses in seven countries [1] Group 2 - Hesai Technology became the first lidar company to achieve a dual primary listing on the Hong Kong Stock Exchange, raising approximately HKD 4.16 billion and reaching a market value of HKD 35.85 billion on its first day [2] - Since the reform of the Hong Kong listing system in 2018, over 30 Chinese concept stocks have returned to Hong Kong, including major players like Alibaba, JD.com, and Baidu, representing a significant portion of the internet sector [2] - There are three main methods for Chinese concept stocks to return to Hong Kong: privatization and re-listing, secondary listings, and dual listings, with 34 companies having returned since 2018 [2] Group 3 - The return of Chinese concept stocks to Hong Kong is seen as a strategic move amid U.S. regulatory and geopolitical uncertainties, providing companies with better funding opportunities and faster listing processes [3] - The industry focus of returning companies has primarily been on internet platforms and biotechnology, with expectations for future expansions into emerging sectors such as semiconductors, industrial software, and intelligent driving [3]

Core Insights - I-Mab is transitioning to NovaBridge Biosciences, focusing on a global biotech innovation platform and plans to dual-list on the Hong Kong Stock Exchange and NASDAQ [1][2] - The company aims to bridge Chinese biotech innovations with global markets, enhancing the value of domestic innovations [2][7] - The "Hub-and-Spoke" model will be adopted, allowing for independent development of various product lines under a centralized management structure [3][4] Company Strategy - The new management team, led by CEO Dr. Fu Xiyong, is focused on recruiting talent to support the transformation and maximize the value of Chinese innovative drugs [2][5] - NovaBridge will leverage its parent company, Kangqiao Capital's resources, to support its global expansion and development strategy [4][6] - The company plans to target clinical-stage projects with high differentiation and competitive advantages, aiming for significant value increases during the clinical trial phases [9][10] Market Context - China has become a hotspot for biopharmaceutical innovation, with a significant increase in drug development activities since 2015, leading to a robust pipeline of innovative drugs [7][8] - The value of BD transactions in China's pharmaceutical sector has surged, with over $66.8 billion in overseas licensing agreements in the first half of 2025 [8] - The company aims to capture a larger share of the value chain, potentially increasing the returns from licensing agreements from 10% to as high as 50% [8][9] Competitive Landscape - NovaBridge's approach is compared to Roivant, but with a broader opportunity set in China, where numerous companies are engaged in drug development [10] - The efficiency and cost-effectiveness of conducting clinical trials in China provide a competitive advantage over Western markets [10] - The company plans to utilize both business development and self-commercialization strategies to maximize the value of its drug pipeline [10][11]

Core Viewpoint - I-Mab held a business update call to discuss recent developments and future outlook, emphasizing the importance of the information shared during the call [2][4]. Group 1: Company Updates - The call was initiated by PJ Kelleher from LifeSci Advisors, indicating a structured approach to investor communication [2]. - The presentation and discussion are recorded and will be accessible on the company's website for 30 days, ensuring transparency and availability of information for investors [2]. Group 2: Forward-Looking Statements - The company made forward-looking statements in accordance with the Private Securities Litigation Reform Act of 1995, highlighting the potential for actual results to differ due to various risks and uncertainties [3]. - I-Mab clarified that any forward-looking statements reflect the company's views as of October 16, 2025, and there is no obligation to update these statements post-call [4].